about
Is NF-kappaB a good target for cancer therapy? Hopes and pitfallsAberrant nuclear factor-kappa B activity in acute myeloid leukemia: from molecular pathogenesis to therapeutic target"Real-world" data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group.Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma.Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study.How I treat plasma cell leukemia.Multiple myeloma in Niger Delta, Nigeria: complications and the outcome of palliative interventions.Multiple myeloma and bone disease: pathogenesis and current therapeutic approaches.Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy.Reiterative survival analyses of total therapy 2 for multiple myeloma elucidate follow-up time dependency of prognostic variables and treatment arms.Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib.Targeting MAGE-C1/CT7 expression increases cell sensitivity to the proteasome inhibitor bortezomib in multiple myeloma cell linesLenalidomide in the treatment of multiple myeloma: a review.Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trialThe interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias.The Medical Research Council Myeloma IX trial: the impact on treatment paradigms.Cancer/Testis Antigen MAGE-C1/CT7: new target for multiple myeloma therapy.Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma.Inhibition of adhesive interaction between multiple myeloma and bone marrow stromal cells by PPARgamma cross talk with NF-kappaB and C/EBPEarly response to bortezomib combined chemotherapy can help predict survival in patients with multiple myeloma who are ineligible for stem cell transplantation.Combination chemotherapy increases cytotoxicity of multiple myeloma cells by modification of nuclear factor (NF)-κB activity.Imaging features of extramedullary, relapsed, and refractory multiple myeloma involving the liver across treatment with cyclophosphamide, lenalidomide, bortezomib, and dexamethasoneGoing with the flow, and beyond, in myeloma.The Arkansas approach to therapy of patients with multiple myeloma.The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo.Phase I/II trial of weekly bortezomib with lenalidomide and dexamethasone in first relapse or primary refractory myeloma.Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice modelSingle-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy.Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols.New targets and treatments in multiple myeloma: Src family kinases as central regulators of disease progression.Fenretinide inhibits myeloma cell growth, osteoclastogenesis and osteoclast viability.Initial therapy in multiple myeloma: investigating the new treatment paradigm.Clinical challenges: Myeloma and concomitant type 2 diabetes.Clinical challenges: myeloma and concomitant type 2 diabetesPomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 studyKidney disease associated with plasma cell dyscrasiasInhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers.Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.Managing multiple myeloma: the emerging role of novel therapies and adapting combination treatment for higher risk settings.Monoclonal antibodies in the treatment of multiple myeloma.
P2860
Q24570128-2DA58C2E-81D9-41D4-BFE4-9782B89B5F86Q26995561-69963473-1039-4FBC-B4EF-690BC2049794Q30657752-182581A3-9FD0-47D1-BD92-08B28C736FC0Q33386405-EB6AEE77-01E0-414F-93CA-710D8687E85FQ33401457-3A9B3F1E-EC2B-4134-BE2D-5826F302262AQ33402555-B730E214-4F55-454A-8C27-9E2390D1C822Q33734421-D8567384-1733-4891-AB59-30328FC49CC8Q33953955-3A7699BE-303C-457B-909B-675A6575BA9DQ33973877-00A81B41-6347-4D6C-9863-794FD3376A2AQ33990944-501C5E84-F662-41C9-95BC-F4CC16B71428Q34008578-0AD3C557-29CE-4199-9D8D-C4DFCC19E755Q34081748-B212FA66-F9AC-4E6B-88C3-FF22449CD734Q34775515-4A45DB5F-7158-47B3-B17A-65572DA4DD75Q35125893-C2CC22E8-589A-421D-91C5-5B64F915EDCDQ35552693-E8AD8C36-D53A-4F22-B5F0-A5641395813FQ35700723-8C1104CC-A8ED-4DA8-A14F-9A066282F21FQ35846167-D7459C41-F65E-4F50-84BF-B029AD14883CQ36162690-885E3486-78D0-4947-B227-9C7B09B5897CQ36447976-4FC59776-7D28-4960-99CD-93B27021B1EEQ36536365-2100D684-E0F6-4DA3-8A0D-E5D5294888C0Q36589122-40725B51-C134-4254-8316-E08C4FD83283Q36920186-831B7335-E0AB-4C36-845E-347D229003CAQ36969834-25D33683-D4AA-4365-813A-7803FE451A41Q37028586-7438CE50-69B2-4DFD-B73D-EEF0EB263D18Q37034189-D018CC67-CBE0-40BC-9F77-9DE3D7030EB4Q37216292-73A051CE-C0CC-4963-9629-EC96AE3037F8Q37223850-5B684289-78FE-4B14-BBED-A26516B636E4Q37280739-7050CC66-6F18-42EA-85FE-232D48F68722Q37306614-408B9C36-331D-443C-9796-29174780AF89Q37340398-ABE80A3C-1C8D-44E3-901F-B195C59585DCQ37344577-FC696DE7-1FC8-4DA6-B21A-3CD6A432516AQ37411805-945B321E-4034-40E6-B474-911361F0656AQ37467309-C5C3A9D6-DE2A-40D8-9DED-E9B03467F59DQ37552667-F7F6A5DA-B7F4-49F0-94FA-63938A12F31AQ37655019-D72079FA-15E7-4C52-A5AA-B099FB643990Q37750106-5B71CE96-0345-41C9-9AF7-CA124DB3E975Q37827173-E020C622-C833-4ED4-BA00-B29FF778C902Q37842346-7B3738A2-83C8-448F-941B-523B21CDA29EQ37898151-28335517-AECF-4BE3-9299-F965E9D916E6Q37903377-3E0C2E5B-5427-4DB3-8F0A-4DFD56BEDB9C
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
New drugs for myeloma.
@en
type
label
New drugs for myeloma.
@en
prefLabel
New drugs for myeloma.
@en
P2093
P1433
P1476
New drugs for myeloma.
@en
P2093
Constantine Mitsiades
Nikhil Munshi
Robert Schlossman
P304
P356
10.1634/THEONCOLOGIST.12-6-664
P577
2007-06-01T00:00:00Z